Hallucinations and delusions appearing for the first time in midlife or later are frequently categorized as psychiatric symptoms of unclear biological origin, but new research published in Molecular Psychiatry reveals they may be linked to dementia-related brain changes. According to the National Institutes for Quantum Science and Technology, about 65 percent of patients who develop psychosis after age 40 show an abnormal buildup of tau protein, which is commonly associated with Alzheimer’s disease.
Tau Buildup Discovered in Late-Onset Psychosis Patients
Researchers utilizing positron emission tomography (PET) scans examined 37 patients with psychosis beginning after age 40 alongside 47 healthy older adults. According to the study, 65 percent of the late-onset psychosis patients showed tau PET positivity using the QST tracer florzolotau (18F). In comparison, only 15 percent of healthy older controls showed similar tau positivity. Furthermore, amyloid PET positivity appeared in 35 percent of patients, while just 2 percent of healthy controls registered positive results.
Patients can show identical symptoms like hallucinations or delusions yet experience vastly different clinical courses and treatment responses. Representative researcher Manabu Kubota noted that the study originated from a clinical question regarding whether hidden biological brain differences could explain those varying paths. Until this study, direct in vivo evidence connecting neurodegeneration to late-life psychotic symptoms remained limited, though earlier epidemiological and postmortem studies suggested a link.
Diverse Brain Pathology Patterns and Cognitive Impact
The PET scans identified distinct patterns of tau accumulation among patients. Some individuals exhibited amyloid-positive patterns typical of Alzheimer’s disease, while others displayed amyloid-negative patterns that point toward non-Alzheimer’s types of tau-related neurodegeneration. In amyloid-negative patients, tau buildup concentrated heavily in posterior brain regions, specifically the parietal and occipital lobes. Researchers indicate this regional accumulation can impair higher cognitive functions such as attention, judgment, and problem-solving.
The study also connected tau buildup directly with cognitive performance. Among amyloid-positive patients, higher tau accumulation in the parietal lobe correlated with lower executive function, which governs planning and attention control. These findings suggest that quantifying tau levels in the brain helps explain specific clinical features observed in late-onset psychosis.
Moving Toward Biomarker-Based Diagnosis
While Alzheimer’s disease diagnosis increasingly relies on detecting amyloid and tau, objective biological tools for hallucinations and delusions have historically remained scarce. Late-onset psychosis places a heavy burden on families, patients, and caregivers, particularly in aging societies. People experiencing these symptoms later in life do not always receive medical care, as psychiatric evaluations alone can make diagnosis and management difficult.
Did You Know? Florzolotau (18F) is a specialized PET tracer that allows researchers to visualize a broad range of tau pathologies directly in the living human brain.
The new findings help shift late-onset psychosis toward earlier diagnosis and intervention anchored in measurable brain changes. Over the long term, researchers aim to use PET-based assessments to support personalized treatments. Identifying whether a patient’s symptoms stem from Alzheimer’s-type or non-Alzheimer’s-type tau pathology could allow doctors to select therapies tailored to the specific underlying disease process.
Frequently Asked Questions
What is late-onset psychosis?
Late-onset psychosis refers to hallucinations, delusions, or related symptoms that appear for the first time in midlife or later, typically after age 40.
How is tau protein linked to psychosis?
Recent PET scan research shows that approximately 65 percent of patients with late-onset psychosis exhibit abnormal tau protein buildup in the brain, mirroring changes seen in dementia.
Can PET scans detect Alzheimer’s-related changes in psychosis patients?
Yes. Studies utilizing amyloid and tau PET imaging can identify both Alzheimer’s-type pathology and non-Alzheimer’s neurodegenerative patterns in patients experiencing psychotic symptoms.
Why are biological tools important for diagnosing midlife psychosis?
Traditional psychiatric evaluations alone can make late-onset psychosis difficult to diagnose and manage. Biomarkers offer objective data to support earlier and more personalized medical interventions.
What are your thoughts on using neuroimaging for psychiatric diagnoses? Leave a comment below, explore our neurology research archive, or subscribe to our newsletter for updates on brain health science.
Related reading